daniele biasci

Research scientist in immunology

[daniele biasci @daniele_1981]

IPO on the Nasdaq is so much fun! #ipo #absci

[daniele biasci @daniele_1981]

@ilyasut People deserve to know why.

[Columbia - Irving Institute for Cancer Dynamics @Cancer_dynamics]

Our Mathematical and Computational Methods in Cancer and Biology Symposium has started. Thank you to our opening speakers: Simon Tavaré, Jeannette Wing, Michael Waterman, and Anil Rustgi.

[daniele biasci @daniele_1981]

@noriko_amanopat Grazie Noriko. Its honestly a lot of fun!!

[daniele biasci @daniele_1981]

IPO on the Nasdaq is so much fun! #ipo #absci

[daniele biasci @daniele_1981]

@CAonline @AmerCancerCEO @AmerCancerCMSO @AmericanCancer @ACS_Research Time for the FED to raise interests rates. Clearly hyperinflation is already here!

[Amit Garg @amgarg]

Congrats @DenizKural, James Sietstra, @Daniele_1981 & team! @TotientBio uses AI to accelerate drug discovery. Absolutely rooting -- your success at @AbSciBio makes the world better. It's the first exit of @TauVentures that @SanjayRao and I started in 2019. https://t.co/HjelzekidS

[daniele biasci @daniele_1981]

We started Totient four years ago with the idea of making fully human antibodies from tertiary lymphoid structures. I am delighted to announce that #Totient was acquired by #AbSci today!

https://t.co/Op5btFCGwE

[Totient Bio @TotientBio]

Totient's manuscript describing the first large scale study of antigens recognized by fully human intratumoral antibodies is now available on bioRxiv.
https://t.co/2B4ZyDdzz6

[daniele biasci @daniele_1981]

Excited to be presenting at the Kennedy Institute in Oxford. I will be sharing some new data on FDCSP+ fibroblasts and immunotherapy response. #Immunotherapy #Immunology

[Mark Hamill @MarkHamill]

Your wish is my command @MalcolmNance, and thanks for fighting the good fight!

#TheForceIsSTRONGWithJoe

[MRC Toxicology Unit @MRC_TU]

A new clinical trial shows it may be possible to expand cancer immunotherapy to help more patients in the future. Computational immunology analysis was led by Daniele Biasci, CAMS Fellow at MRC Tox Unit. Here's the link to the press release from CRUK
https://t.co/4sBC7CQ6Js

[daniele biasci @daniele_1981]

This was a very nicely planned phase 1 trial, with biopsies collected before and during therapy, and RNAseq data from both. The amount of information we got from it was incredible. With scRNAseq going mainstream, things will only get better...

[CRUK Cambridge Institute @CRUK_CI]

New research from the Jodrell Group & @JanowitzTobias @CSHL reports on a drug which induces an integrated immune response in cancers that do not usually respond to #Immunotherapy.

Read more👇
https://t.co/je8ih4149N

[AtomsTalk @AtomsTalk]

# Researchers Find Effective Immunotherapy Against Non-Responsive Cancer Types

Researchers: @daniele_1981, @JanowitzTobias
Institutes: @Cambridge_Uni, @CRUKCamCentre, @CSHL, @CRUK_CI
Publication: @PNASNews

#nes #cancer #CancerResearch #MedTwitter
https://t.co/6VXE5kyKnI

[daniele biasci @daniele_1981]

Finally published!
https://t.co/f9kiCvTzLO

[daniele biasci @daniele_1981]

@InesBarroso4 Seriously??

[daniele biasci @daniele_1981]

Totient partnered with Integral Molecular to screen antibodies from human tumors against one of the world's largest (6000!) collection of native human membrane proteins. This is going to be really cool...
https://t.co/rtFmMwdgaA

[daniele biasci @daniele_1981]

@MaggieAstor hi Maggie, I am not trump fan but your article contains a big error: the Regeneron cocktail is well into phase 3 https://t.co/gOS03MCfPo

[daniele biasci @daniele_1981]

@Margolis73 They reached out to clarify the article.

[daniele biasci @daniele_1981]

Incredibly, Fox News is calling “polyclonal antibodies” the two monoclonal antibodies administered to President Trump. We really need to do better: correct scientific communication makes everyone safer. #immunology #antibodies #covid19pandemic #foxnews https://t.co/91Ap7enmXd

[daniele biasci @daniele_1981]

@Margolis73 I guess they both have a lot of “room for improvement”...

[daniele biasci @daniele_1981]

To Fox News credit, they reached out already to clarify the issue.